| 000 | 01765 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517183105.0 | ||
| 264 | 0 | _c20181015 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1365-2893 | ||
| 024 | 7 |
_a10.1111/jvh.12820 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCannizzo, E S | |
| 245 | 0 | 0 |
_aUnconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study. _h[electronic resource] |
| 260 |
_bJournal of viral hepatitis _c04 2018 |
||
| 300 |
_a381-390 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aSustained Virologic Response |
| 650 | 0 | 4 |
_aT-Lymphocyte Subsets _ximmunology |
| 650 | 0 | 4 |
_aTenofovir _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aTincati, C | |
| 700 | 1 | _aBinda, F | |
| 700 | 1 | _aRonzi, P | |
| 700 | 1 | _aCazzaniga, F A | |
| 700 | 1 | _aAntinori, S | |
| 700 | 1 | _ad'Arminio Monforte, A | |
| 700 | 1 | _aMarchetti, G | |
| 700 | 1 | _aMilazzo, L | |
| 773 | 0 |
_tJournal of viral hepatitis _gvol. 25 _gno. 4 _gp. 381-390 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jvh.12820 _zAvailable from publisher's website |
| 999 |
_c27742605 _d27742605 |
||